S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.
Alexander Peikert,Parag Goyal,Muthiah Vaduganathan,Brian Claggett,Ian J. Kulac,Zi Michael Miao,Orly Vardeny,Mikhail Kosiborod,Akshay S. Desai,Pardeep S. Jhund,Carolyn S.P. Lam,Silvio E. Inzucchi,Felipe Martinez,W. De Boer,Adrian F. Hernandez,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon +18 more
TL;DR: The DELIVER trial as mentioned in this paper evaluated the efficacy and safety of adding dapagliflozin according to the number of concomitant medications in patients with mild reduced or preserved ejection fraction.
Journal ArticleDOI
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Journal ArticleDOI
Effect of Dapagliflozin on Health Status and Quality-of-Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF & DELIVER Trials.
Ankeet S. Bhatt,Mikhail Kosiborod,Muthiah Vaduganathan,Brian Claggett,Zi Michael Miao,Ian J. Kulac,Carolyn S.P. Lam,Adrian F. Hernandez,Felipe Martinez,Silvio E. Inzucchi,W. De Boer,Pardeep S. Jhund,Akshay S. Desai,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon +16 more
TL;DR: In this paper , the authors examined the effects of dapagliflozin on health status, measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), across the full spectrum of left ventricular ejection fraction (LVEF).